Poster Presentations: Wednesday, October 26, 2011 |

Reduction in the Risk of Initial and Subsequent Exacerbations Following Roflumilast Treatment: Pooled Results From Two Pivotal Trials FREE TO VIEW

Fernando Martinez, MD; Amir Sharafkhaneh, MD; Klaus Rabe, MD; Udo-Michael Goehring, MD; Manja Brose, MS; Dirk Bredenbroeker, MD; Hassan Lakkis, PhD; Paul Rowe, MD; Ulo Palm, MD
Chest. 2011;140(4_MeetingAbstracts):555A. doi:10.1378/chest.1118272
Text Size: A A A
Published online


PURPOSE: Disease severity is associated with increased frequency of acute exacerbations of COPD (AECOPD). Some patients experience repeated AECOPD. These frequent AECOPD result in decreased quality of life, increased hospitalizations, and mortality. Therefore, preventing not only the first AECOPD event but also subsequent exacerbations is likely important. Roflumilast is approved to reduce the risk of AECOPD in COPD patients with severe spirometric disease, chronic bronchitis, and a history of AECOPD. This post hoc analysis examines the effect of roflumilast in delaying the time to first AECOPD and its effects on reducing the risk of subsequent AECOPD events (up to the 5th).

METHODS: Roflumilast (500 μg QD) was examined in two 52-week pivotal trials (M2-124 and M2-125) in severe-to-very severe COPD patients with ≥1 moderate or severe AECOPD in the previous year. Data were pooled for the efficacy of roflumilast compared with placebo for median days to first moderate or severe AECOPD (Kaplan-Meier estimate), and hazard ratios (HR) for first, second, third, fourth, and fifth moderate or severe AECOPD (Cox proportional hazards model).

RESULTS: A total of 3091 patients were treated with roflumilast (n=1537) or placebo (n=1554). As previously shown, the median time to first AECOPD was longer with roflumilast (303 days) than placebo (236 days). The results below enumerate the HR for time to AECOPD for roflumilast compared with placebo. 1st AECOPD HR=0.886 (95% CI 0.802-0.980; P=0.019) 2nd AECOPD HR=0.791 (95% CI 0.685-0.914; P=0.001) 3rd AECOPD HR=0.730 (95% CI 0.593-0.899; P=0.003) 4th AECOPD HR=0.596 (95% CI 0.437-0.814; P=0.001) 5th AECOPD HR=0.477 (95% CI 0.297-0.764; P=0.002)

CONCLUSIONS: Roflumilast significantly delayed time to the first AECOPD, while also decreasing the risk of up to a fifth AECOPD in severe-to-very severe COPD patients compared with placebo.

CLINICAL IMPLICATIONS: These data suggest a decrease in exacerbation burden with roflumilast therapy.

DISCLOSURE: Fernando Martinez: Consultant fee, speaker bureau, advisory committee, etc.: GSK, MedImmune/Astra Zeneca, Merck, Pearl, Novartis, UBC, Forest/Almirall, Actelion, Boehringer Ingelheim, Nycomed/Forest, Ikaria, Roche, Bayer, Schering, HLS, Talecris, Comgenix, fb Communications, BoomComm and Actelion, NACE, MedEd, Potomac, Pfizer, Schering, Vox Medic, American Lung Association, WebMD, ePocrates, Astra Zeneca, France Foundation, CMEincite and Altana/Nycomed, Grant monies (from industry related sources): Boehringer Ingelheim, Other: Associates in Medical Marketin, Castle Connolly, France Foudation, HIT Global and ePocrates

Amir Sharafkhaneh: Consultant fee, speaker bureau, advisory committee, etc.: GSK, AZ, DEY, Pfizer and BI, Grant monies (from industry related sources): GSK, AZ, DEY, Pfizer, BI and Forest

Klaus Rabe: Consultant fee, speaker bureau, advisory committee, etc.: AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, Forest, GlaxoSmithKline, Merck, Novartis, Nycomed, and Pfizer, Grant monies (from industry related sources): Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche

Udo-Michael Goehring: Employee: Nycomed GmbH

Manja Brose: Employee: Nycomed GmbH

Dirk Bredenbroeker: Employee: Nycomed GmbH

Hassan Lakkis: Employee: Forest Research Institute

Paul Rowe: Employee: Forest Research Institute

Ulo Palm: Employee: Forest Research Institute

No Product/Research Disclosure Information

09:00 AM - 10:00 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543